Research programme: cell-based therapeutics - Q Therapeutics

Drug Profile

Research programme: cell-based therapeutics - Q Therapeutics

Alternative Names: Astrocyte-based therapeutics - Q Therapeutics; Glial cell-based therapeutic (Q-Cells) - Q Therapeutics; Q-Cells; Transplanted human GRPs - Q Therapeutics

Latest Information Update: 27 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Utah
  • Developer Drexel University College of Medicine; Johns Hopkins University; Q Therapeutics
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis; Demyelinating disorders; Spinal cord injuries

Most Recent Events

  • 25 Jul 2017 The US FDA approves IND application for a phase I/IIa trial in Transverse myelitis
  • 03 Jul 2015 Q Therapeutics plans a phase I/II trial in Amyotrophic lateral sclerosis in USA (NCT02478450)
  • 04 Jun 2015 The US FDA approves IND application for Q-cells™ in Amyotrophic lateral sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top